Delving into the Latest Updates on Dalian Wanchun Biotechnology Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Founded in the year 2010, Dalian Wanchun Bulin Pharmaceutical Co Ltd. is a company dedicated to the research and development of innovative drugs, with a particular emphasis on novel therapies for cancer treatment.

Tags

Congenital Disorders

Immune System Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

GEF-H1 x KRAS	1

在早期（I期和II期）及III期乳腺癌（淋巴结阳性或淋巴结阴性且复发风险较高）患者中比较第1周期的重度中性粒细胞减少症持续时间。在筛选时（第1周期TAC给药前）和第1周期第1、2、3、6、7、8、9、10、11、12、13和15天（给药日给药前；其他日的时间与给药日给药前大致相当）评估中性粒细胞绝对计数。

[Translation]

Duration of severe neutropenia during Cycle 1 was compared in patients with early-stage (stage I and II) and stage III breast cancer (node-positive or node-negative at high risk of recurrence). Assess absolute neutrophil counts at screening (before TAC administration in Cycle 1) and on Cycle 1 Days 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, and 15 (before dosing on dosing day; other days are roughly equivalent to before dosing on dosing day).

Start Date15 Oct 2019

Sponsor / Collaborator

BeyondSpring Pharmaceuticals, Inc.

[+2]

CTR20180713 / CompletedPhase 3

在接受多西他赛骨髓抑制化学疗法的实体瘤患者中,评价普那布林对比培非格司亭的重度中性粒细胞减少症持续时间

[Translation] Evaluation of plinabulin versus pegfilgrastim for duration of severe neutropenia in patients with solid tumors receiving myelosuppressive chemotherapy with docetaxel

主要目的是评估采用多西他赛+普那布林对比多西他赛+培非格司亭治疗第1周期的重度中性粒细胞减少症持续时间。次要目的是骨痛，中性粒细胞减少症发生率，感染发生率，发热性中性粒细胞减少症的发生率以及有其所致的住院发生率及持续时间。

[Translation]

The primary objective was to assess the duration of severe neutropenia in docetaxel plus plinabulin versus docetaxel plus pegfilgrastim during cycle 1. Secondary objectives were bone pain, the incidence of neutropenia, the incidence of infections, the incidence of febrile neutropenia, and the incidence and duration of hospitalizations due to neutropenia.

Start Date29 May 2018

Sponsor / Collaborator

BeyondSpring Pharmaceuticals, Inc.

[+2]

CTR20171050 / CompletedPhase 2

在接受TAC骨髓抑制化学疗法的乳腺癌患者中,评价普那布林对比培非格司亭的重度中性粒细胞减少症持续时间

[Translation] Evaluation of plinabulin versus pegfilgrastim for duration of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy with TAC

根据药代动力学（PK）/药效学（PD）分析，确定III期推荐剂量（RP3D）

[Translation]

Determine the Phase III recommended dose (RP3D) based on pharmacokinetic (PK)/pharmacodynamic (PD) analysis

Start Date13 Dec 2017

Sponsor / Collaborator

BeyondSpring Pharmaceuticals, Inc.

[+2]

100 Clinical Results associated with Dalian Wanchun Biotechnology Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Dalian Wanchun Biotechnology Co. Ltd.

Login to view more data

100 Deals associated with Dalian Wanchun Biotechnology Co. Ltd.

Login to view more data

100 Translational Medicine associated with Dalian Wanchun Biotechnology Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

Login to view more data